Mon05202019

Robins Global News & Noticias



  • Shipping Advice
    Shipping Advice
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association


MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that updated data from its ongoing Phase 1b/2 clinical trial evaluating 5F9 in combination with rituximab for the treatment of relapsed/refractory non-Hodgkin’s lymphoma (r/r NHL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), will be presented in an oral presentation at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, Netherlands, June 13-16, 2019.
In an additional oral presentation, Forty Seven will present initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These data in AML and MDS will have been previously presented in a poster session on Monday, June 3, 2019 at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.Details on the presentations are as follows:Presentation Title: The first-in-class anti-CD47 antibody HU5F9-G4 with rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: interim phase 1b/2 results
Oral Session Title: Aggressive Lymphomas – New Agents
Presentation Date & Time: Saturday, June 15, 2019 from 16:15-16:30 CEST (10:15 a.m. – 10:30 a.m. ET)
Abstract Code: S867
Location: Hall 5
Presentation Title: The first-in-class anti-CD47 antibody HU5F9-G4 is active and well tolerated alone or in combination with azacitidine in AML and MDS patients: initial phase 1b results
Oral Session Title: New Therapies in AML
Presentation Date & Time: Saturday, June 15, 2019 from 16:30-16:45 CEST (10:30 a.m. – 10:45 a.m. ET)
Abstract Code: S878
Location: Elicium 2
The accepted abstracts are now available online on the EHA website: https://ehaweb.org/congress/eha24/key-information/.About Forty Seven Inc.:
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developin...


Posted: 2019-05-16 13:01:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting

Tue, 12 Feb 2019 00:00:00 GMT

Highlights of Actinium's key meeting activities are: Late Breaking Oral Presentation Title: Novel Re-Induction and Anti-CD45 Targeted Conditioning with Iodine (131I) Apamistamab [Iomab-B] Yields ...

Celgene’s Revlimid gets a win in late-stage lymphoma

Tue, 24 Jul 2018 03:37:00 GMT

Celgene has new phase III data that could add yet another string to blockbuster Revlimid’s bow – as a treatment for patients with non-Hodgkin’s lymphoma ... Revlimid lymphoma trials – MAGNIFY pairing ...

Nordic Nanovector ASA: Invitation to First Quarter 2017 Results Presentation and Webcast

Tue, 16 May 2017 07:14:00 GMT

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma ... ...

Nordic Nanovector ASA: Invitation to First Quarter 2017 Results Presentation and Webcast

Tue, 16 May 2017 06:51:00 GMT

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma ... ...

Nordic Nanovector ASA: Invitation to First Quarter 2017 Results Presentation and Webcast

Tue, 16 May 2017 02:45:00 GMT

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma ... ...

Related Bing Web Search

医薬品・医療機器産業の企業ニュース

(Fri, 17 May 2019 14:51:00 GMT)

ジョンソン・エンド・ジョンソン株式会社 :コンシューマー、医薬品、医療機器でビジネスを展開。 医薬品の売上高世界7位(2006年) 12/3 【その他】 先行購入者アンケート満足度96%! アキュビュー® ディファイン® 新デザイン 全国一般発売開始

Related News Story Videos From Youtube

Primary mediastinal large b-cell lymphoma (PMBL): Helen's story


Related Videos On: Primary mediastinal large b-cell lymphoma (PMBL): Helen's story


Joanne Crowther's Story:Beating lymphoma with Cannabis Oil (MORE at cureyourowncancer.org)


Related Videos On: Joanne Crowther's Story:Beating lymphoma with Cannabis Oil (MORE at cureyourowncancer.org)


Idelalisib for Previously Treated CLL


Related Videos On: Idelalisib for Previously Treated CLL


Ongoing studies by the German CLL study group (GCLLSG)


Related Videos On: Ongoing studies by the German CLL study group (GCLLSG)






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.